ARK Investment Management LLC Sells 10,668 Shares of Amgen Inc. $AMGN

Key Points

• ARK Investment Management LLC reduced its stake in Amgen by 18.4% in Q3, selling 10,668 shares and leaving 47,265 shares valued at about $13.34 million.
• Amgen beat Q4 expectations with $5.29 EPS vs. $4.76 expected and $9.87 billion in revenue, and set FY 2026 guidance of 21.60–23.00 EPS versus analyst estimates near 20.62.
• The board declared a quarterly dividend of $2.52 per share (annualized $10.08) with an ex-dividend date of May 15 and a yield of about 2.7%.

ARK Investment Management LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,265 shares of the medical research company's stock after selling 10,668 shares during the period. ARK Investment Management LLC's holdings in Amgen were worth $13,338,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the 2nd quarter worth approximately $27,000. Evelyn Partners Investment Management LLP purchased a new position in Amgen in the second quarter worth $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen during the second quarter worth $32,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen during the 3rd quarter valued at $34,000. Finally, Nvwm LLC boosted its position in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company's stock worth $42,000 after purchasing an additional 134 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on AMGN. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They set a "sector outperform" rating and a $385.00 target price on the stock. Freedom Capital downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. The Goldman Sachs Group lifted their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a "buy" rating in a research note on Wednesday, February 4th. UBS Group boosted their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Finally, Wells Fargo & Company raised their price target on shares of Amgen from $325.00 to $375.00 and gave the stock an "equal weight" rating in a report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $354.17.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board declared a $2.52 per‑share dividend for Q2 2026 — a cash return and yield support that tends to be received positively by income and value investors. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen advanced its blinatumomab franchise with a new Phase 3 subcutaneous trial — if successful, a subcutaneous formulation can broaden use, improve patient convenience, and extend commercial life. This is a clinically material development for future revenue potential. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Positive Sentiment: Stock reached an annual high within a Nasdaq‑100 rally — positive technical momentum and index strength can attract flows and lift shares. Amgen NASDAQ: AMGN Hits Annual High Within The Nasdaq 100 Index Rally
• Neutral Sentiment: Broader media and analyst coverage (Zacks, Yahoo Finance pieces) is raising investor attention but contains mainly summaries and guidance rechecks rather than new fundamental catalysts. Increased coverage can boost trading volume and visibility. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Industry and market reports (asthma market outlook, competitor regulatory moves) are circulating; these are background items to monitor for longer‑term impact but not immediate stock drivers. 7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
• Neutral Sentiment: Short‑interest entries in recent feeds report a "significant increase" but show zero shares/NaN figures — this appears to be a data error rather than a genuine surge in shorting. Until reliable short‑interest data is available, treat these reports cautiously. (Data entries from March 3–4 appear inconsistent.)

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $379.27 on Thursday. The company has a 50 day simple moving average of $351.83 and a two-hundred day simple moving average of $321.58. The stock has a market cap of $204.45 billion, a price-to-earnings ratio of 26.65, a PEG ratio of 3.74 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. During the same quarter last year, the company posted $5.31 earnings per share. The firm's revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen's dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.